4.2 Article

Tumor Necrosis Factor-Like Weak Inducer of Apoptosis Activates Type I Interferon Signals in Lupus Nephritis

Journal

BIOMED RESEARCH INTERNATIONAL
Volume 2017, Issue -, Pages -

Publisher

HINDAWI LTD
DOI: 10.1155/2017/4927376

Keywords

-

Funding

  1. Suzhou City Ke Jiao Xing Wei Project [KJXW2016011]
  2. National Natural Science Foundation of China [81200507]
  3. Second Affiliated Hospital of Soochow University [XKQ2015003]

Ask authors/readers for more resources

Type I interferon (IFN) plays a central role in pathogenesis of systemic lupus erythematosus (SLE); tumor necrosis factor-like weak inducer of apoptosis (TWEAK) has been associated with a pathogenic role in lupus nephritis (LN). Thus we investigated whether TWEAK could induce the activation of type I IFN pathway in LN. We examined this in patient-derived peripheral blood mononuclear cells (PBMCs) as well as MRL/lpr mice, a murine LN model. Relative to the control cohorts, MRL/lpr mice showed severe histological changes, high index levels of renal damage, and elevated expression of type I IFN-inducible genes. After shRNA suppression of TWEAK, we observed that renal damage was significantly attenuated and expression of type I IFN-inducible genes was reduced in MRL/lpr mice. In parallel, siRNA of TWEAK also significantly reduced the expression of type I IFN-inducible genes in PBMCs relative to control transfections. In PBMCs, TWEAK stimulation also led to expression of type I IFN-inducible genes. Our results illustrate a novel regulatory role of TWEAK, in which its activity positively regulates type I IFN pathway in LN based on preclinical models. Our findings suggest TWEAK could act as a critical target in preventing renal damage in patients with LN.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Letter Dermatology

Tofacitinib for the treatment of refractory or glucocorticoid-dependent cutaneous leukocytoclastic vasculitis

Jinlu Ma, Wentian Lu, Dong Yan, Zhichun Liu, Leixi Xue

DERMATOLOGIC THERAPY (2022)

Article Rheumatology

Utility of the ACR-1997, SLICC-2012 and EULAR/ACR-2019 classification criteria for systemic lupus erythematosus: a single-centre retrospective study

Wentian Lu, Ying Zhong, Chenghua Weng, Qing Wang, Mei Tang, Zhichun Liu, Leixi Xue

Summary: This study compared the diagnostic performance of three different versions of classification criteria in Chinese patients with SLE and found that SLICC-2012 and EULAR/ACR-2019 showed good early diagnosis ability.

LUPUS SCIENCE & MEDICINE (2022)

Letter Rheumatology

Association of change in metabolic syndrome status with altered risk of incident gout: comment on the article by Eun et al

Gang Wang, Ning Zhuo, Mei Tang, Leixi Xue, Zhichun Liu

ARTHRITIS & RHEUMATOLOGY (2023)

Article Rheumatology

Tumour-associated antigens in systemic lupus erythematosus: association with clinical manifestations and serological indicators

Ying Zhong, Zhichun Liu, Jinlu Ma, Lin Zhang, Leixi Xue

Summary: This retrospective study aimed to investigate the relationship between tumour-associated antigens (TAAs) and the clinical manifestations and serological markers of SLE. The results showed that SLE patients had higher positivity rates for TAAs such as CA19-9 and CYFRA21-1, and elevated levels of CA125, CA15-3, and CYFRA21-1. Thrombocytopenia and serum creatinine levels were identified as independent risk factors for TAA positivity in SLE patients. In addition, CA125 positivity rate and serum CA125 levels were associated with SLE disease activity.

RHEUMATOLOGY (2023)

No Data Available